Misplaced Pages

Difluprednate

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Corticosteroid drug Pharmaceutical compound
Difluprednate
Clinical data
Trade namesDurezol
AHFS/Drugs.comMonograph
MedlinePlusa609025
License data
Routes of
administration		Eye drops
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • phenanthren-17-yl] butanoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.041.636 Edit this at Wikidata
Chemical and physical data
FormulaC27H34F2O7
Molar mass508.559 g·mol
3D model (JSmol)
SMILES
  • 12CC(OC(=O)CCC)(C(=O)COC(C)=O)1(C)C(O)1(F)2()C(F)C2=CC(=O)C=C12C
InChI
  • InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1
  • Key:WYQPLTPSGFELIB-JTQPXKBDSA-N
  (what is this?)  (verify)

Difluprednate, sold under the brand name Durezol, is a corticosteroid used for the treatment of post-operative ocular inflammation and pain.

It was approved for medical use in the United States in June 2008. It is available as a generic medication.

Medical uses

Difluprednate is indicated for the treatment of inflammation and pain associated with ocular surgery; and the treatment of endogenous anterior uveitis.

Clinical trials

Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a phase 3 study evaluating difluprednate for the treatment of anterior uveitis

References

  1. ^ "Durezol emulsion". DailyMed. 11 July 2022. Retrieved 7 March 2023.
  2. "Drug Approval Package: Durezol (Difluprednate) NDA #022212". U.S. Food and Drug Administration (FDA). 25 July 2008. Retrieved 7 March 2023.
  3. "Sirion Therapeutics Announces FDA Approval of Durezol for Treatment of Postoperative Ocular Inflammation and Pain" (Press release). Sirion Therapeutics, Inc. 2008-06-24. Retrieved 2008-06-30.
  4. "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  5. Clinical trial number NCT00501579 for "Study of Difluprednate in the Treatment of Uveitis" at ClinicalTrials.gov
  6. Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS (May 2014). "Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study". Investigative Ophthalmology & Visual Science. 55 (5): 2993–3002. doi:10.1167/iovs.13-12660. PMC 4581692. PMID 24677110.
Glucocorticoids and antiglucocorticoids (D07, H02)
Glucocorticoids
Natural
Synthetic
Antiglucocorticoids
Synthesis modifiers
See also
Glucocorticoid receptor modulators
Mineralocorticoids and antimineralocorticoids
List of corticosteroids
Glucocorticoid receptor modulators
GRTooltip Glucocorticoid receptor
Agonists
Mixed
(SEGRMsTooltip Selective glucocorticoid receptor agonists)
Antagonists
Others
See also
Receptor/signaling modulators
Glucocorticoids and antiglucocorticoids
Mineralocorticoid receptor modulators
List of corticosteroids


Stub icon

This dermatologic drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: